Patrick J. Heron - 14 Jun 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Director, 10%+ Owner
Signature: /s/ David Topper, Attorney-in-Fact for Patrick J. Heron
Issuer symbol: ARQT
Transactions as of: 14 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 18 Jun 2024, 16:52:14 UTC
Previous filing: 30 Apr 2025
Next filing: 10 Sep 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Award	$0	+10,139	+117%	$0.000000	18,826	14 Jun 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARQT	Stock Option (right to buy)	Award	$0	+27,052		$0.000000	27,052	14 Jun 2024	Common Stock	27,052	$8.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2	The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

Content

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.